SAKK 01/18: Reduced intensity radio-chemotherapy for Stage IIA/B seminoma. A multicenter, open label phase II trial with two cohorts

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509663-24-00

Acronym

SAKK 01/18

Enrollment

Registered

2024-08-12

Start date

2020-08-20

Completion date

Unknown

Last updated

2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IIA/B seminoma

Brief summary

Progression free survival (PFS) at 3 years

Detailed description

Response rate (RR), Progression free survival (PFS), Time to progression (TTP), Overall Survival (OS), Seminoma-specific survival, Time to distant metastasis, Time to next treatment, Localization of progression, Method of detection of progression

Interventions

DRUGCarboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGEtomedac 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGCisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Response rate (RR), Progression free survival (PFS), Time to progression (TTP), Overall Survival (OS), Seminoma-specific survival, Time to distant metastasis, Time to next treatment, Localization of progression, Method of detection of progression	—

Primary

Measure	Time frame
Progression free survival (PFS) at 3 years	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026